SomaLogic signs collaborative agreement with Novo Nordisk to support drug development efforts

BOULDER, Colo. (June 28, 2021)—SomaLogic, Inc., a global leader in proteomics technology, announced today that it is adding to its list of collaborative agreements with global healthcare innovator, Novo Nordisk. As part of the agreement, Novo Nordisk will expand the use of the SomaScan® technology platform for their drug development research in non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetes.

Novo Nordisk will also provide proteins to SomaLogic that will help expand their proteomics platform to 10,000 proteins, more than six times the protein menu offerings of the current competitors. Novo Nordisk used SomaLogic’s SomaSignal™ tests in previous drug development efforts and will continue to use the tests as part of this agreement.

“SomaSignal tests offer deep insights into human health and give our customers an important tool in their work in drug research and development,” said SomaLogic’s Executive Vice President, Life Sciences Markets Tracy Hervey. “This collaborative agreement will support Novo Nordisk in their drug discovery work and in the clinical development of potentially life saving therapies.”

Each SomaSignal test is built on SomaLogic’s proprietary SomaScan Platform, which offers what is believed to be the broadest view available of the proteome. The platform is capable of potentially identifying new biomarkers, novel drug targets and improving the assessment and management of therapeutic responses. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 450,000 samples to date.

 

###

 

SomaLogic Contact

Emilia Costales
720-798-5054

ecostales@somalogic.com

 

About SomaLogic
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary, and personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

SomaSignal™ tests are developed and performance characteristics determined by SomaLogic, Inc. SomaLogic is a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.

SomaSignal™ tests are for Research Use Only (RUO) and have not been cleared or approved by the US Food and Drug Administration for diagnostic or patient management purposes.

 

Forward Looking Statements Disclaimer

Certain matters discussed throughout this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, our use of words such as “expect,” “anticipate,” “believe,” “should,“ “estimate,” “intend,” “strategy,” “future,” “opportunity,” “will,” “forecast,” “plan,” “project,” “assume” or similar words of futurity identify such forward-looking statements. These forward-looking statements are based on current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such statements may relate to projections of the Company’s revenue, earnings and other business plans, financial and operational measures, Company debt levels, ability to repay outstanding indebtedness, payment of dividends, and future operations, among other matters. We caution you not to place undue reliance on any such forward-looking statements. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Forward-looking statements speak only as of the date they are made. You are cautioned not to put undue reliance on forward-looking statements.

 

 

Sign up to receive our news releases